search
Back to results

SPL026 With or Without SSRIs in Participants With MDD

Primary Purpose

Major Depressive Disorder

Status
Completed
Phase
Phase 1
Locations
United Kingdom
Study Type
Interventional
Intervention
SPL026
Sponsored by
Small Pharma Ltd
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Major Depressive Disorder focused on measuring Major Depressive Disorder, MDD, Depression, SSRI, N,N-dimethyltryptamine, DMT

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • MDD diagnosis
  • Previously tried at least one approved method of treatment for their depression
  • No monoamine oxidase-inhibitor class antidepressants for at least 3 months
  • Deemed healthy on the basis of a clinical history, physical examination, ECG, vital signs, laboratory tests of blood and urine
  • No psychedelic drug use in the 6 months before dosing until the end of the study
  • Willing to follow the contraception requirements of the trial
  • Willing to be contacted by email and video call, and have online access
  • Able to give fully informed written consent
  • Test Cohort only: currently on a stable dose of an unspecified single SSRI alone and not in combination with any other psychiatric medications, for at least 6 weeks prior to Screening with no intention of making any changes
  • Control Cohort only: no antidepressant medication for 6 months before dosing

Exclusion Criteria:

  • Substance use disorder
  • Current or clinically relevant history of a psychotic disorder, or first-degree relatives with a clinically relevant history of a psychotic disorder
  • Significant history of mania
  • Significant risk of suicide
  • Clinically relevant abnormal findings at the screening assessment
  • Blood pressure, heart rate, or QTcF outside the acceptable ranges
  • Acute or chronic illness (other than MDD) or infection
  • Clinically relevant abnormal medical history or concurrent medical condition (other than MDD)
  • Use of any serotonergic psychedelics within 6 months prior to dosing
  • Patients of child-bearing potential who are pregnant or lactating, or who are sexually active and not using a reliable method of contraception
  • History of a severe adverse reaction to any drug or sensitivity to serotonergic psychedelic drugs
  • Use of over-the-counter or prescribed medication (excluding oral contraceptives, hormone replacement therapy and SSRIs [Test Cohort only]) within previous 28 day before dose of trial medication; or paracetamol or ibuprofen within 4 hours prior to dosing

Sites / Locations

  • Mac Clinical Research
  • MAC Clinical Research

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

Test Cohort

Control Cohort

Arm Description

Patients who are currently taking an SSRI that is not effective in fully relieving their depression (prescribed outside of study). Patients will be administered a single dose of SPL026 by intravenous infusion.

Patients who are not currently taking any pharmacological treatment for their depression. Patients will be administered a single dose of SPL026 by intravenous infusion.

Outcomes

Primary Outcome Measures

Safety & tolerability: Adverse Events
Adverse events (AEs)
Safety & tolerability: Lab biochemistry
Values of potential clinical importance
Safety & tolerability: Vital signs - Heart Rate
Heart rate
Safety & tolerability: Vital signs - Blood pressure
Blood pressure
Safety & tolerability: Vital signs - Temperature
Temperature
Safety & tolerability: Electrocardiogram
QTcX intervals
Safety & tolerability: Suicidal Ideation
Columbia-Suicide Severity Rating Scale

Secondary Outcome Measures

Evaluation of plasma levels of DMT
Pharmacokinetic parameter calculation in the Test Cohort compared to the Control Cohort
Mystical Experience Questionnaire (MEQ)
MEQ in the Test Cohort compared to the Control Cohort
Challenging Experience Questionnaire (CEQ)
CEQ in the Test Cohort compared to the Control Cohort
Ruminative Responses Scale (RRS)
RRS in the Test Cohort compared to the Control Cohort
Warwick-Edinburgh Mental Wellbeing Scale (WEMWBS)
WEMWBS in the Test Cohort compared to the Control Cohort

Full Information

First Posted
September 13, 2022
Last Updated
August 10, 2023
Sponsor
Small Pharma Ltd
search

1. Study Identification

Unique Protocol Identification Number
NCT05553691
Brief Title
SPL026 With or Without SSRIs in Participants With MDD
Official Title
An Open-Label Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics & Exploratory Efficacy of Intravenous SPL026 Drug Product (DMT Fumarate) Alone or in Combination With SSRIs in Patients With Major Depressive Disorder
Study Type
Interventional

2. Study Status

Record Verification Date
August 2023
Overall Recruitment Status
Completed
Study Start Date
December 13, 2022 (Actual)
Primary Completion Date
August 3, 2023 (Actual)
Study Completion Date
August 3, 2023 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Small Pharma Ltd

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The main aim of the study is to test the safety and tolerability of single doses of SPL026 (N,N-dimethyltryptamine [DMT] fumarate, a psychedelic tryptamine) in patients currently taking a selective serotonin reuptake inhibitor (SSRI) for their depression, but for whom the SSRI is not fully relieving their depression.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Major Depressive Disorder
Keywords
Major Depressive Disorder, MDD, Depression, SSRI, N,N-dimethyltryptamine, DMT

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Parallel Assignment
Model Description
Test Cohort of patients already taking an SSRI for their depression, compared to the Control Cohort who are not already taking an SSRI. All patients will receive SPL026
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
18 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Test Cohort
Arm Type
Experimental
Arm Description
Patients who are currently taking an SSRI that is not effective in fully relieving their depression (prescribed outside of study). Patients will be administered a single dose of SPL026 by intravenous infusion.
Arm Title
Control Cohort
Arm Type
Experimental
Arm Description
Patients who are not currently taking any pharmacological treatment for their depression. Patients will be administered a single dose of SPL026 by intravenous infusion.
Intervention Type
Drug
Intervention Name(s)
SPL026
Other Intervention Name(s)
N,N-dimethyltryptamine, DMT
Intervention Description
Intravenous
Primary Outcome Measure Information:
Title
Safety & tolerability: Adverse Events
Description
Adverse events (AEs)
Time Frame
Screening to End-of-Study Follow-up (Day 29)
Title
Safety & tolerability: Lab biochemistry
Description
Values of potential clinical importance
Time Frame
Screening, Day -1 and Day 1
Title
Safety & tolerability: Vital signs - Heart Rate
Description
Heart rate
Time Frame
Screening to Day 2
Title
Safety & tolerability: Vital signs - Blood pressure
Description
Blood pressure
Time Frame
Screening to Day 2
Title
Safety & tolerability: Vital signs - Temperature
Description
Temperature
Time Frame
Screening to Day 2
Title
Safety & tolerability: Electrocardiogram
Description
QTcX intervals
Time Frame
Screening to Day 2
Title
Safety & tolerability: Suicidal Ideation
Description
Columbia-Suicide Severity Rating Scale
Time Frame
Screening to End-of-Study Follow-up (Day 29)
Secondary Outcome Measure Information:
Title
Evaluation of plasma levels of DMT
Description
Pharmacokinetic parameter calculation in the Test Cohort compared to the Control Cohort
Time Frame
2, 5, 7, 10, 11, 13, 15, 30, 60, 120, 240 minutes post-dose
Title
Mystical Experience Questionnaire (MEQ)
Description
MEQ in the Test Cohort compared to the Control Cohort
Time Frame
Day 1 (dosing day)
Title
Challenging Experience Questionnaire (CEQ)
Description
CEQ in the Test Cohort compared to the Control Cohort
Time Frame
Day 1 (dosing day)
Title
Ruminative Responses Scale (RRS)
Description
RRS in the Test Cohort compared to the Control Cohort
Time Frame
Day -1 and Day 29
Title
Warwick-Edinburgh Mental Wellbeing Scale (WEMWBS)
Description
WEMWBS in the Test Cohort compared to the Control Cohort
Time Frame
Day -1, Day 15 and Day 29
Other Pre-specified Outcome Measures:
Title
Exploratory efficacy: Montgomery-Åsberg Depression Rating Scale (MADRS)
Description
MADRS in the Test Cohort compared to the Control Cohort
Time Frame
Day -1, Day 8, Day 15 and Day 29

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: MDD diagnosis Previously tried at least one approved method of treatment for their depression No monoamine oxidase-inhibitor class antidepressants for at least 3 months Deemed healthy on the basis of a clinical history, physical examination, ECG, vital signs, laboratory tests of blood and urine No psychedelic drug use in the 6 months before dosing until the end of the study Willing to follow the contraception requirements of the trial Willing to be contacted by email and video call, and have online access Able to give fully informed written consent Test Cohort only: currently on a stable dose of an unspecified single SSRI alone and not in combination with any other psychiatric medications, for at least 6 weeks prior to Screening with no intention of making any changes Control Cohort only: no antidepressant medication for 6 months before dosing Exclusion Criteria: Substance use disorder Current or clinically relevant history of a psychotic disorder, or first-degree relatives with a clinically relevant history of a psychotic disorder Significant history of mania Significant risk of suicide Clinically relevant abnormal findings at the screening assessment Blood pressure, heart rate, or QTcF outside the acceptable ranges Acute or chronic illness (other than MDD) or infection Clinically relevant abnormal medical history or concurrent medical condition (other than MDD) Use of any serotonergic psychedelics within 6 months prior to dosing Patients of child-bearing potential who are pregnant or lactating, or who are sexually active and not using a reliable method of contraception History of a severe adverse reaction to any drug or sensitivity to serotonergic psychedelic drugs Use of over-the-counter or prescribed medication (excluding oral contraceptives, hormone replacement therapy and SSRIs [Test Cohort only]) within previous 28 day before dose of trial medication; or paracetamol or ibuprofen within 4 hours prior to dosing
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Fabian Devlin, MD
Organizational Affiliation
MAC Clinical Research
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Neel Bhatt, MD
Organizational Affiliation
MAC Clinical Research
Official's Role
Principal Investigator
Facility Information:
Facility Name
Mac Clinical Research
City
Manchester
State/Province
Greater Manchester
ZIP/Postal Code
M13 9NQ
Country
United Kingdom
Facility Name
MAC Clinical Research
City
Liverpool
State/Province
Prescot
ZIP/Postal Code
L34 1BH
Country
United Kingdom

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

SPL026 With or Without SSRIs in Participants With MDD

We'll reach out to this number within 24 hrs